These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 14525902)

  • 21. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases.
    Schepkens H; Vanholder R; Billiouw JM; Lameire N
    Am J Med; 2001 Apr; 110(6):438-41. PubMed ID: 11331054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Let's read the domestic literature. ACE-inhibitors and spironolactone-induced hyperkalemia].
    Radó J
    Orv Hetil; 2002 Aug; 143(31):1868; author reply 1868. PubMed ID: 12187583
    [No Abstract]   [Full Text] [Related]  

  • 23. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
    J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors for hyperkalaemia in a cohort of patients with newly diagnosed heart failure: a nested case-control study in UK general practice.
    Michel A; Martín-Pérez M; Ruigómez A; García Rodríguez LA
    Eur J Heart Fail; 2015 Feb; 17(2):205-13. PubMed ID: 25581138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Malignant arrhythmias caused by hyperkalemia: a new area of drug-induced electrolyte abnormalities].
    Tomcsányi J; Somlói M; Arabadzisz H; Horváth L
    Orv Hetil; 2002 Mar; 143(13):663-6. PubMed ID: 11975043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonism.
    Poggio R; Grancelli HO; Miriuka SG
    Postgrad Med J; 2010 Mar; 86(1013):136-42. PubMed ID: 20237007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spironolactone in patients with heart failure.
    Vanpee D; Swine C
    N Engl J Med; 2000 Jan; 342(2):133; author reply 133-4. PubMed ID: 10636753
    [No Abstract]   [Full Text] [Related]  

  • 28. Elderly heart failure patients with drug-induced serious hyperkalemia.
    Vanpee D; Swine CH
    Aging (Milano); 2000 Aug; 12(4):315-9. PubMed ID: 11073352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spironolactone-potion or poison?
    Drug Ther Bull; 2017 Feb; 55(2):13. PubMed ID: 28153847
    [No Abstract]   [Full Text] [Related]  

  • 30. Spironolactone use and renal toxicity: population based longitudinal analysis.
    Wei L; Struthers AD; Fahey T; Watson AD; Macdonald TM
    BMJ; 2010 May; 340():c1768. PubMed ID: 20483947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preventable sudden death in patients receiving angiotensin converting enzyme inhibitors and loop/potassium sparing diuretic combinations.
    Johnston RT; de Bono DP; Nyman CR
    Int J Cardiol; 1992 Feb; 34(2):213-5. PubMed ID: 1737674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hyperkalemia in ambulant postcardiac surgery patients during combined therapy with angiotensin-converting enzyme inhibitor, spironolactone, and diet rich in potassium: A report of two cases and review of literature.
    Dixit A; Majumdar G; Tewari P
    Ann Card Anaesth; 2019; 22(2):162-168. PubMed ID: 30971598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of combined angiotensin-converting enzyme inhibitors and spironolactone on serum K+, Mg 2+, and Na+ concentrations in small dogs with degenerative mitral valve disease.
    Thomason JD; Rockwell JE; Fallaw TK; Calvert CA
    J Vet Cardiol; 2007 Nov; 9(2):103-8. PubMed ID: 17983885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spironolactone for heart failure.
    Med Lett Drugs Ther; 1999 Sep; 41(1061):81-2. PubMed ID: 10505071
    [No Abstract]   [Full Text] [Related]  

  • 35. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
    Han SW; Won YW; Yi JH; Kim HJ
    Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A patient with severe hyperkalaemia -- an emergency after RALES].
    Nürnberger J; Daul A; Philipp T
    Dtsch Med Wochenschr; 2005 Sep; 130(36):2008-11. PubMed ID: 16143930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Ineffective atrial pacing and cardiac arrest in a 80-year old woman with hyperkalemia].
    Lelakowski J; Czunko A; Majewski J; Pasowicz M; Małecka B; Bednarek J
    Pol Merkur Lekarski; 2005 May; 18(107):566-7. PubMed ID: 16161957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR; Rolfe M
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
    Tamirisa KP; Aaronson KD; Koelling TM
    Am Heart J; 2004 Dec; 148(6):971-8. PubMed ID: 15632880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spironolactone in patients with heart failure.
    Larkin RJ; Atlas SA; Donohue TJ
    N Engl J Med; 2000 Jan; 342(2):132-3; author reply 133-4. PubMed ID: 10636751
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.